WallStSmart

Innate Pharma (IPHA)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Innate Pharma generates 1114% more annual revenue ($9.01M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).

IPHA

Avoid

11

out of 100

Grade: F

Growth: 2.0Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 2/9Altman Z: -12.05

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

IPHA1 strengths · Avg: 10.0/10
Debt/EquityHealth
-1.0410/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

IPHA4 concerns · Avg: 2.8/10
Market CapQuality
$170.90M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-271.4%2/10

ROE of -271.4% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : IPHA

The strongest argument for IPHA centers on Debt/Equity.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : IPHA

The primary concerns for IPHA are Market Cap, Profit Margin, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

IPHA is growing revenue faster at -46.7% — sustainability is the question.

IPHA generates stronger free cash flow (-23M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RVMD scores higher overall (24/100 vs 11/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Innate Pharma

HEALTHCARE · BIOTECHNOLOGY · USA

Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France and internationally. The company is headquartered in Marseille, France.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?